Results 231 to 240 of about 80,532 (301)

Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective?

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Ovarian Cancer (OC), the deadliest gynecological malignancy, poses a major therapeutic challenge in advanced stages owing to its high recurrence rate and metastatic potential. In this regard, it is noteworthy that immunotherapy has recently gained significant attention in OC treatment, a phenomenon attributable to notable advances in over‐the ...
Liying Wang, Yisen Cao, Yuan Ren, Yuhang Zhang, Liang Wang   +4 more
wiley   +1 more source

Glypican-3-Specific CAR NK Cells Co-Secreting IL-15 and IFN-α Have Increased Anti-Tumor Function Versus Hepatocellular Carcinoma In Vitro. [PDF]

Int J Mol Sci
Busà R, Iannolo G, Douradinha B, Pagano D, Gallina A, Cappello G, La Rocca A, Gruttadauria S, Conaldi PG, Badami E.   +9 more
europepmc   +1 more source

Computational Design of an mRNA Vaccine Targeting LRP6 for Triple‐Negative Breast Cancer Therapy

Cancer Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Triple‐negative breast cancer (TNBC) presents a poorer prognosis than other breast cancer subtypes, attributed to its aggressive nature and the lack of specific therapeutic interventions. TNBC has high recurrence rates and limited survival despite current therapies, emphasizing the critical need for improved treatment options.
Pooriya Teimoori, Mohammadreza Heidari
wiley   +1 more source

Enhanced Fc and complement activity of Fc‐modified avelumab boosts anti‐tumor activity but promotes NK cell fratricide

Clinical &Translational Immunology, Volume 15, Issue 5, 2026.
Abstract Objectives The anti‐PD‐L1 antibody avelumab has demonstrated efficacy across multiple cancer types. Avelumab primarily blocks the PD‐1/L1 immune checkpoint, while inducing antibody‐dependent cellular cytotoxicity (ADCC) from CD16a+ NK cells.
Lachlan J Dobson, Barry D Hock, Ariana HT Drabble, Liping Goddard, Judith L McKenzie, Sean A MacPherson, Alexander D McLellan   +6 more
wiley   +1 more source

CD19 CAR NK-Cell Therapy in Leukemia & Lymphoma

Oncology Times, 2020
openaire   +2 more sources

In vivo CAR therapies: Turning the patient into their own CAR factory

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Over the past decade, ex vivo autologous chimeric antigen receptor (CAR)‐T‐cell therapies have reshaped the treatment of B‐cell malignancies. Despite their remarkable clinical efficacy, their application remains limited by complex manufacturing processes, demanding logistics, long turnaround times, and substantial costs. In vivo CAR approaches
François Vilcot, Carole‐Anne Brugère, Jaime Fuentealba, Roch Houot   +3 more
wiley   +1 more source

Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing. [PDF]

J Immunother Cancer
Wang M, Krueger JB, Gilkey AK, Stelljes EM, Kluesner MG, Pomeroy EJ, Skeate JG, Slipek NJ, Lahr WS, Claudio Vázquez PN, Zhao Y, Bell JB, Clement K, Eaton EJ, Laoharawee K, Chang JW, Webber BR, Moriarity BS.   +17 more
europepmc   +1 more source

CRISPR Genome Editing and the Future of Leukaemia Immunotherapy

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Leukaemia presents ongoing therapeutic challenges due to relapse and toxicity associated with standard treatments. By enabling more targeted and safer therapies, CRISPR genome editing is emerging as a powerful tool to address these issues.
Dejin Rai, Umberto Terranova
wiley   +1 more source

Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Background The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has ...
Nima Javanmehr, Asal Moazzami Ashtyani, Robabehbeygom Ghafelehbashi, Fateme Mousavi, Hossein Teimouri   +4 more
wiley   +1 more source